Will the recent positive trend continue leading up to its next earnings release, or is Beam Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Total revenues, comprising license and collaboration revenues, came in at $7.4 million in the first quarter compared with $24.2 million in the year-ago period. The top line missed the Zacks Consensu ...

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on June 13-16, 202 ...

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on June 13-16, 202 ...

Beam Therapeutics Inc. (BEAM) incurred a loss of $1.21 per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.45. The company had recorded a loss of $1.33 per share in the year-ago quarter.Total revenues, comprising license and collaboration revenues, came in at $7.4 million in the first quarter compared with $24.2 million in the year-ago period. The top line missed the Zacks Consensus Estimate of $14 million.Quarter in DetailResearch and development expenses amou ...

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and ...

All of these statements are subject to known and unknown important risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forwardlooking statements and should be evaluated as such. Without limiting the foregoing, the words "anticipate," "expect," ...

Exhibit 99.1 Key 2024 Anticipated Milestones Beam expects that its cash, cash equivalents and marketable securities as of March 31, 2024, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2027. This expectation includes funding directed toward reaching each of the key anticipated milestones for BEAM-101, ESCAPE, BEAM-301 and BEAM-302 described above, as well as continued investments in platform advancements and manufacturing capabilities. Contacts: ...

Beam Therapeutics Inc. (BEAM) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the s ...

Key PointsBeam Therapeutics is a pioneer in its proprietary gene-editing technique called base editing.Base editing can be more precise than CRISPR/Cas9 by changing just a single letter in the genome rather than cutting through double strands to cut out specific sequences.Beam Therapeutics surprised investors, beating EPS by $2.42 at $1.73 vs. a loss of 69 cents as revenues surged 1,481% to $316.2 million vs $34.12 million, mostly due to its Eli Lilly deal.5 stocks we like better than Beam TherapeuticsBeam ...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference, emerging genetic therapy approaches corporate panel discussion on Wednesday, March 6, 2024 at 12:50 p.m. ETLeerink Partners Global Biopharma Conference, fireside chat on Monday, March 11, 2024 at ...